PEDIATRIC ONCOLOGY GROUP

这一提议代表着支持继续参与的请求 儿科肿瘤组（POG） 这项合作研究是 致力于研究化疗和其他新的创新 治疗急性白血病和其他肿瘤疾病的方法 童年。 显著缓解和延长生存期， 在临床药理学方面取得了一定的成就和贡献。 然而，这些研究的真实的目的是根除 肿瘤疾病的治疗。 正在设计研究以反映 对肿瘤细胞的攻击强度不断增加。 合作社 分组技术允许在一系列合理规模的 化疗中有希望的线索 这些线索或新方法往往是 这是由该小组自己在临床肿瘤学方面的工作结果提出的。 因此，一个完整的协议往往表明新的途径，以探索 新协议 POG还导致了对免疫表型的研究， 急性淋巴细胞白血病与预后的关系及设计 相应的治疗方案。 儿科血液学/肿瘤科 加州大学圣地亚哥分校的儿科进行了一项为期10年的 参与癌症和白血病组B的合作组研究 在1980年加入POG之前 我们一直是世界上 患者登记研究的贡献者。 在过去 4年（1984年11月至1988年11月），我们共入组457例患者， 方案研究。 从1988年5月到1989年5月， 110例患者从UCSD入组。 Faith Kung博士和Alice Yu博士都是主席 小组治疗方案（-白血病，霍奇金病和新药物）。 余博士的实验室也作为集团参考实验室， 肿瘤标志物脱氧共福霉素GD 2的药理学研究 神经母细胞瘤 韦恩斯普鲁斯博士积极参与团体协议 关于骨髓移植 赫克托·詹姆斯博士在脑瘤 以马克思 William托马斯博士是研究方案的研究协调员， 生殖细胞肿瘤的治疗 John Fontanesi博士是 在小组协议研究的神经心理学测试设计背后， 低拉德小脑星形细胞瘤和视路肿瘤。 我们计划 我们将继续积极参与POG活动的各个阶段。

This proposal represents a request to support continued participation in the Pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic and other new innovative approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant palliation and prolongation of survival has been achieved and contributions have been made in clinical pharmacology. However, the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG also led in the investigation of immunophenotyping of acute lymphoblastic leukemia, correlating it with prognosis and designing appropriate treatment protocols accordingly. The Division of Pediatric Hematology/Oncology in the Department of Pediatrics at the University of California, San Diego had a 10 year involvement in cooperative group studies with Cancer and Leukemia Group B prior to joining forces with POG in 1980. We have been one of the major contributors in patient registry to group protocol studies. In the last 4 years (Nov. 1984 - Nov. 1988), we have entered 457 patients on Group protocol studies. For the year from May 1988 through May 1989, there were 110 patients entered from UCSD. Both Drs. Faith Kung and Alice Yu chair group therapeutic protocols (-leukemia, Hodgkin's disease and new agents). Dr. Yu's laboratory also serves as the group reference laboratory for the study of the pharmacology of deoxycoformycin GD2, a tumor marker for neuroblastoma. Dr. Wayne Spruce is actively involved with group protocols on bone marrow transplantation. Dr. Hector James serves on the Brain Tumor Committee. Dr. William Thomas is a study coordinator for the protocol on the treatment of germ cell tumors. Dr. John Fontanesi is the driving force behind the design of neuropsychological testing for group protocol studies on low rade cerebellar astrocytomas and visual pathway tumors. We plan to continue our active participation in all phases of POG activities.